Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Sales of Eli Lilly’s (LLY) blockbuster weight-loss drug Zepbound surged in the fourth quarter despite missing the company’s initial sales expectations. Zepbound sales reached $1.9 billion in ...

Plus, check out our handy semaglutide weight loss dosage chart for an easy-to-follow overview ... 1 receptor agonist to help with weight loss. Zepbound (tirzepatide) and Saxenda (liraglutide ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

GLP-1 drugs Mounjaro and Zepbound drive a big revenue increase for the drugmaker Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

Tirzepatide is FDA-approved for weight loss as the brand-name drug Zepbound. It is also FDA-approved for type 2 diabetes management as the brand-name drug Mounjaro. Doctors can prescribe Mounjaro ...

This could reduce the cost of Zepbound to $168 per month. Many health insurance plans don't cover the weight loss drug Zepbound because it's so new. It was approved by the FDA at the end of 2023.

Results from a separate trial that were released in 2022 showed patients taking a high dose of Lilly's (LLY.N), opens new tab Zepbound saw more than 20% weight loss. "The results give us greater ...